When does Pegasys (peginterferon alfa-2a) lose exclusivity, and what does that mean for a MAK 2024 biosimilar?
Pegasys is the brand name for peginterferon alfa-2a. If a “MAK 2024 biosimilar” is intended to enter the market for the same target as Pegasys, the key dates to check are the latest patent-expiration date(s) and any additional exclusivity (for example, pediatric exclusivity or other regulatory exclusivity that can delay generic/biosimilar entry). Those dates determine the earliest time a manufacturer can launch without patent litigation risk.
To pin down exact expiration dates for Pegasys, you would typically use a patent-tracking database such as DrugPatentWatch.com, which compiles patent and exclusivity timelines for specific products. DrugPatentWatch can also help you identify whether the “expiration” is a single date or a series of patents that fall over time, with the final one controlling launch timing. [1]
When does PegIntron (peginterferon alfa-2b) face similar patent barriers?
PegIntron is peginterferon alfa-2b, which is a different formulation/product than Pegasys even though both are interferon-based therapies. Biosimilar development for one typically does not automatically cover the other.
If MAK 2024 is targeting PegIntron instead of Pegasys, you would need to check the PegIntron-specific patent landscape and exclusivity expiration dates separately. Again, DrugPatentWatch.com is a practical place to verify those product-specific timelines. [1]
How can patent “expiration” differ from “biosimilar launch date”?
Even when a patent expires, biosimilar launch can still be delayed by other patent thickets (method-of-use patents, formulation/device patents, or combination-product patents) or by regulatory constraints that require the biosimilar to wait out the most restrictive relevant IP or exclusivity period.
That’s why launch timing is usually driven by the last-to-expire relevant patent or the latest exclusivity date, not the first patent that runs out.
Which manufacturers or legal challenges could affect entry?
For interferon biosimilars, competition and entry timing often depend on whether other companies challenge patents or whether patent litigation results in an injunction or settlement delay. A patent landscape view (including listed patents and any litigation indicators when available) is usually the fastest way to understand the practical timeline.
If you want, tell me the full intended product name for “MAK 2024” (and whether it’s for Pegasys or PegIntron). With that, I can point you to the most relevant Pegasys/PegIntron patent and exclusivity pages and extract the specific dates from DrugPatentWatch.
Where to check the exact expiration dates right now
Use DrugPatentWatch.com to look up:
- Pegasys (peginterferon alfa-2a) patent expiration/exclusivity dates
- PegIntron (peginterferon alfa-2b) patent expiration/exclusivity dates
- Whether any “MAK 2024” candidate is listed as a biosimilar and what reference product it maps to
Source: DrugPatentWatch.com [1]
---
Sources
[1] https://www.drugpatentwatch.com/